Skip to main content

Zaltrap FDA Approval History

FDA Approved: Yes (First approved August 3, 2012)
Brand name: Zaltrap
Generic name: ziv-aflibercept
Dosage form: Injection
Company: Sanofi and Regeneron Pharmaceuticals, Inc.
Treatment for: Colorectal Cancer

Zaltrap (ziv-aflibercept) is an angiogenesis inhibitor for the combination treatment of patients with metastatic colorectal cancer.

Development timeline for Zaltrap

Aug  3, 2012Approval FDA Approves Zaltrap for Metastatic Colorectal Cancer
Apr  5, 2012Sanofi and Regeneron Announce Regulatory and Clinical Update for Zaltrap (aflibercept)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.